3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Hepatocellular
3
Recurrence
2
Pleural Effusion, Malignant
2
Mesothelioma, Malignant
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
NSCLC
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Lymphedema
1
Leukemia, Myeloid, Chronic-Phase
1
Immunoglobulin Light-chain Amyloidosis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Glioblastoma
1
Fibrosis
1
Fallopian Tube Neoplasms
1
Dysplastic Nevus Syndrome
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
Cyclophosphamide
28
Temozolomide
25
Irinotecan
21
dinutuximab
20
Topotecan
15
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Biopsy
12
naxitamab
11
Granulocyte-Macrophage Colony-Stimulating Factor
11
3-Iodobenzylguanidine
11
Vincristine
10
Etoposide
10
sargramostim
9
Melphalan
9
Isotretinoin
9
fludarabine
8
X-Rays
8
Colony-Stimulating Factors
8
Carboplatin
8
etoposide phosphate
7
Phantoms, Imaging
7
Doxorubicin
7
fludarabine phosphate
6
Stem Cell Transplantation
6
Nuclear Medicine Department, Hospital
6
Eflornithine
6
Thiotepa
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
Pharmaceutical Preparations
×
1 year
×
Clear all
NCT07334301
2026-01-12
BEACON2
University of Birmingham
Phase 1/2
Recruiting
160 enrolled